Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease

Journal of Crohn's and Colitis

Volumn 6, Issue 4, 2012, Pages 464-469

  Noth, Rainer ^a   Stüber, Eckhard ^a   Häsler, Robert ^b   Nikolaus, Susanna ^a   Kühbacher, Tanja ^a   Hampe, Jochen ^a   Bewig, Burkhard ^a   Schreiber, Stefan ^a,b   Arlt, Alexander ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Anti TNF ; Intestinal permeability; Mucosal healing

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; LACTULOSE; MANNITOL; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; AMPEROMETRY; ANION EXCHANGE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFECT; FEMALE; HUMAN; INTESTINE FUNCTION; INTESTINE MUCOSA PERMEABILITY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROHN DISEASE; FEMALE; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; INTESTINES; LACTULOSE; MALE; MANNITOL; MIDDLE AGED; PERMEABILITY; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84860125647     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.10.004     Document Type: Article

References (47)

1. Han X. Intestinal permeability as a clinical surrogate endpoint in the development of future Crohn's disease therapies. Recent Pat Inflamm Allergy Drug Discov 2011, 4(2):159-176.
2. Suenaert P., Bulteel V., Vermeire S., Noman M., Van Assche G., Rutgeerts P. Hyperresponsiveness of the mucosal barrier in Crohn's disease is not tumor necrosis factor-dependent. Inflamm Bowel Dis 2005, 11(7):667-673.
3. Suenaert P., Bulteel V., Lemmens L., Noman M., Geypens B., Van Assche G., et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002, 97(8):2000-2004.
4. Zeissig S., Bojarski C., Buergel N., Mankertz J., Zeitz M., Fromm M., et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut 2004, 53(9):1295-1302.
5. Soderholm J.D., Streutker C., Yang P.C., Paterson C., Singh P.K., McKay D.M., et al. Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha. Gut 2004, 53(12):1817-1824.
6. Fries W., Renda M.C., Lo Presti M.A., Raso A., Orlando A., Oliva L., et al. Intestinal permeability and genetic determinants in patients, first-degree relatives, and controls in a high-incidence area of Crohn's disease in Southern Italy. Am J Gastroenterol 2005, 100(12):2730-2736.
7. Buhner S., Buning C., Genschel J., Kling K., Herrmann D., Dignass A., et al. Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation?. Gut 2006, 55(3):342-347.
8. Soderholm J.D., Olaison G., Lindberg E., Hannestad U., Vindels A., Tysk C., et al. Different intestinal permeability patterns in relatives and spouses of patients with Crohn's disease: an inherited defect in mucosal defence?. Gut 1999, 44(1):96-100.
9. D'Inca R., Annese V., di Leo V., Latiano A., Quaino V., Abazia C., et al. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease. Aliment Pharmacol Ther 2006, 23(10):1455-1461.
10. Wehkamp J., Schmid M., Stange E.F. Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr Opin Gastroenterol 2007, 23(4):370-378.
11. Rosenstiel P., Jacobs G., Till A., Schreiber S. NOD-like receptors: ancient sentinels of the innate immune system. Cell Mol Life Sci 2008, 65(9):1361-1377.
12. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134(2):577-594.
13. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Lofberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lemann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol;106(2):199-212; quiz 213.
14. Rutgeerts P., Van Deventer S., Schreiber S. Review article: the expanding role of biological agents in the treatment of inflammatory bowel disease-focus on selective adhesion molecule inhibition. Aliment Pharmacol Ther 2003, 17(12):1435-1450.
15. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2011, 362(15):1383-1395.
16. Irvine E.J., Marshall J.K. Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology 2000, 119(6):1740-1744.
17. Wyatt J., Vogelsang H., Hubl W., Waldhoer T., Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993, 341(8858):1437-1439.
18. Malin M., Isolauri E., Pikkarainen P., Karikoski R., Isolauri J. Enhanced absorption of macromolecules. A secondary factor in Crohn's disease. Dig Dis Sci 1996, 41(7):1423-1428.
19. Arnott I.D., Kingstone K., Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 2000, 35(11):1163-1169.
20. D'Inca R., Di Leo V., Corrao G., Martines D., D'Odorico A., Mestriner C., et al. Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol 1999, 94(10):2956-2960.
21. Bjarnason I., MacPherson A., Hollander D. Intestinal permeability: an overview. Gastroenterology 1995, 108(5):1566-1581.
22. Lahesmaa-Rantala R., Magnusson K.E., Granfors K., Leino R., Sundqvist T., Toivanen A. Intestinal permeability in patients with yersinia triggered reactive arthritis. Ann Rheum Dis 1991, 50(2):91-94.
23. Bjarnason I., Peters T.J. In vitro determination of small intestinal permeability: demonstration of a persistent defect in patients with coeliac disease. Gut 1984, 25(2):145-150.
24. Mahendra P., Bedlow A.J., Ager S., Ancliff P.J., Wraight E.P., Marcus R.E. Technetium (99mTc)-labelled white cell scanning, 51Cr-EDTA and 14C-mannitol-labelled intestinal permeability studies: non-invasive methods of diagnosing acute intestinal graft-versus-host disease. Bone Marrow Transplant 1994, 13(6):835-837.
25. Andre C., Andre F., Colin L., Cavagna S. Measurement of intestinal permeability to mannitol and lactulose as a means of diagnosing food allergy and evaluating therapeutic effectiveness of disodium cromoglycate. Ann Allergy 1987, 59(5 Pt 2):127-130.
26. Ukabam S.O., Clamp J.R., Cooper B.T. Abnormal small intestinal permeability to sugars in patients with Crohn's disease of the terminal ileum and colon. Digestion 1983, 27(2):70-74.
27. Laker M.F., Bull H.J., Menzies I.S. Evaluation of mannitol for use as a probe marker of gastrointestinal permeability in man. Eur J Clin Invest 1982, 12(6):485-491.
28. Weaver L.T., Laker M.F., Nelson R. Intestinal permeability in the newborn. Arch Dis Child 1984, 59(3):236-241.
29. Fordtran J.S., Rector F.C., Ewton M.F., Soter N., Kinney J. Permeability characteristics of the human small intestine. J Clin Invest 1965, 44(12):1935-1944.
30. Iwata H., Matsushita M., Nishikimi N., Sakurai T., Nimura Y. Intestinal permeability is increased in patients with intermittent claudication. J Vasc Surg 2000, 31(5):1003-1007.
31. Goebel A., Buhner S., Schedel R., Lochs H., Sprotte G. Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome. Rheumatology (Oxford) 2008, 47(8):1223-1227.
32. Benjamini Y., Hochberg Y. A practical and powerful approach to multiple testing. J R Stat Soc B Methodol 1995, 57:289-300.
33. van Assche G., Vermeire S., Rutgeerts P. Mucosal healing and anti TNFs in IBD. Curr Drug Targets 2010, 11(2):227-233.
34. Nusrat A., Turner J.R., Madara J.L. Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am J Physiol Gastrointest Liver Physiol 2000, 279(5):G851-G857.
35. Schulzke J.D., Fromm M. Tight junctions: molecular structure meets function. Ann N Y Acad Sci 2009, 1165:1-6.
36. Marchiando A.M., Shen L., Graham W.V., Edelblum K.L., Duckworth C.A., Guan Y., et al. The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal epithelial shedding. Gastroenterology 2011.
37. Hering N.A., Schulzke J.D. Therapeutic options to modulate barrier defects in inflammatory bowel disease. Dig Dis 2009, 27(4):450-454.
38. Gibson P.R. Increased gut permeability in Crohn's disease: is TNF the link?. Gut 2004, 53(12):1724-1725.
39. Hollander D. Crohn's disease, TNF-alpha, and the leaky gut. The chicken or the egg?. Am J Gastroenterol 2002, 97(8):1867-1868.
40. Vilela E.G., Torres H.O., Ferrari M.L., Lima A.S., Cunha A.S. Gut permeability to lactulose and mannitol differs in treated Crohn's disease and celiac disease patients and healthy subjects. Braz J Med Biol Res 2008, 41(12):1105-1109.
41. Wyatt J., Oberhuber G., Pongratz S., Puspok A., Moser G., Novacek G., et al. Increased gastric and intestinal permeability in patients with Crohn's disease. Am J Gastroenterol 1997, 92(10):1891-1896.
42. Fries W., Muja C., Crisafulli C., Cuzzocrea S., Mazzon E. Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies. Am J Physiol 2008, 294(4):G938-G947.
43. Vos AC, Wildenberg ME, Duijvestein M, Verhaar AP, van den Brink GR, Hommes DW. Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology;140(1):221-30.
44. Di Sabatino A., Rosado M.M., Cazzola P., Biancheri P., Tinozzi F.P., Laera M.R., et al. Splenic function and IgM-memory B cells in Crohn's disease patients treated with infliximab. Inflamm Bowel Dis 2008, 14(5):591-596.
45. Bourreille A., Ignjatovic A., Aabakken L., Loftus E.V., Eliakim R., Pennazio M., et al. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy 2009, 41(7):618-637.
46. Dionisio P.M., Gurudu S.R., Leighton J.A., Leontiadis G.I., Fleischer D.E., Hara A.K., et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. Am J Gastroenterol 2011, 105(6):1240-1248. [quiz 1249].
47. Intestinal permeability as a clinical surrogate endpoint in the development of future Crohn's disease therapies. Recent patents on inflammation & allergy drug discovery;4(2):159-76.